26th Apr 2006 18:12
Hikma Pharmaceuticals Plc26 April 2006 Annual Information Update LONDON, 26 April 2006. In accordance with Prospectus Rule 5.2, HikmaPharmaceuticals PLC ("Hikma" or "the Company")(LSE: HIK) sets out below asummary of the information which has been published or made available to thepublic over the previous 12 months. The information referred to in this Updatewas up to date at the time the information was published, but some informationmay now be out of date. Stock Exchange announcements Announcements made by the Company via RNS, a Regulatory Information Service, maybe viewed and downloaded from the London Stock Exchange website (www.londonstockexchange.com/marketnews) or from the press releases page on theCompany's website at (http://investors.hikma.com/hikma/regulatorynews.jsp). TheStock Exchange announcements made during the defined period are: Date of announcement Headline of announcement 25 Apr 2006 Hikma to list Global Depository Receipts on DIFX21 Apr 2006 Notification of Transaction19 Apr 2006 Hikma acquires JPI03 Apr 2006 Block listing29 Mar 2006 Hikma Preliminary Results25 Jan 2006 Hikma Announces FDA Approval23 Jan 2006 Trading Statement05 Dec 2005 Director/PDMR Shareholding30 Nov 2005 Over allotment option28 Nov 2005 Renewal of Contract04 Nov 2005 Director/PDMR Shareholding02 Nov 2005 Publication of Prospectus01 Nov 2005 Stabilisation Notice01 Nov 2005 Pricing Announcement17 Oct 2005 Hikma Pharmaceutials announces intention to float Documents filed with the Financial Services Authority The company has filed the following documents with the Financial ServicesAuthority ("FSA") over the previous 12 months. These documents are or will beavailable to be viewed via the FSA's Document Viewing Facility or at theCompany's registered office. Date filed with the FSA Document filed with the FSA 26 Apr 2006 Annual report and accounts26 Apr 2006 Notice of Annual General Meeting01 Nov 2005 Prospectus Documents filed with Companies House The Company has made the following filings with Companies House. Copies of thesedocuments may be obtained from Companies House, Crown Way, Maindy, Cardiff CF143UZ or, if you are a registered user, they may be viewed and downloaded usingCompanies House Direct at www.direct.companieshouse.gov.uk. The Companies Housefilings made during the defined period are: Date filed with Document filed with Companies HouseCompanies House 26 Apr 2006 2005 Annual report and accounts26 Apr 2006 Notice of Annual General Meeting13 Feb 2006 Form 123 - Notice of increase in share capital13 Feb 2006 Form 122 - Notice of sub-division13 Feb 2006 Authorisation of allotment of securities17 Jan 2006 Form 288a - Director appointed29 Nov 2005 Form 288a - Director appointed29 Nov 2005 Form 288a - Director appointed29 Nov 2005 Form 288a - Director appointed07 Nov 2005 Adoption of Memorandum of Association and Articles of Association28 Oct 2005 Company name change23 Sep 2005 Approval of change of rights of all shares23 Sep 2005 Memorandum of Association and Articles of Association19 Sep 2005 Company name change22 Sep 2005 Form 288a - Director appointed22 Sep 2005 Form 288a - Secretary appointed22 Sep 2005 Form 288a - Director appointed22 Sep 2005 Form 288a - Director resigned; Secretary resigned22 Sep 2005 Form 288a - Director resigned22 Sep 2005 Form 225 - Change of accounting reference date16 Sep 2005 Authorisation to commence business and borrow16 Sep 2005 Form 117 - Application to commence business08 Sep 2005 Incorporation documents In addition, the Company filed Forms 88(2) - Return of Allotment of Shares withCompanies House. These were posted on the Companies House Direct website on 13February 2006 and 22 September. Henry KnowlesCompany Secretary27 April 2006 - ENDS - Enquiries: Hikma Pharmaceuticals plc +44 20 7479 4870Henry Knowles, Company Secretary +44 20 7479 4893Susan Ringdal, Investor Relations DirectorBrunswick Group LLP +44 20 7404 5959Jon Coles / Wendel Verbeek / Justine McIlroy / AlexTweed Notes to Editors About HikmaHikma Pharmaceuticals PLC is a multinational pharmaceutical group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: Generic, Branded and InjectablePharmaceuticals. Hikma's operations are based principally in the United States,the Middle East and North Africa ("MENA") region and Europe. In 2005, the Grouphad revenue of $262 million and profit attributable to shareholders of $44million. At 31 December 2005, the Group had over 1,800 employees. For news andother information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hikma Pharmaceuticals